» Articles » PMID: 27777308

Molecular Determinants of Scaffold-induced Linear Ubiquitinylation of B Cell Lymphoma/Leukemia 10 (Bcl10) During T Cell Receptor and Oncogenic Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2016 Oct 26
PMID 27777308
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

The activation of NF-κB downstream of T cell receptor (TCR) engagement is a key signaling step required for normal lymphocyte function during the adaptive immune response. During TCR signaling, the adaptor protein Bcl10 is inducibly recruited to the CARD11 scaffold protein as part of a multicomponent complex that induces IκB kinase (IKK) activity and NF-κB activation. Here, we show that a consequence of this recruitment is the TCR-induced conjugation of Bcl10 with linear-linked polyubiquitin chains to generate the signaling intermediate Lin(Ub)-Bcl10, which is required for the association of Bcl10 with the NEMO subunit of the IKK complex. The TCR-induced generation of Lin(Ub)-Bcl10 requires Bcl10 lysines 17, 31, and 63, CARD11, MALT1, and the HOIP subunit of the linear ubiquitin chain assembly complex (LUBAC) but not the HOIP accessory protein SHARPIN. CARD11 promotes signal-induced Lin(Ub)-Bcl10 generation by co-recruiting Bcl10 with HOIP, thereby bringing substrate to enzyme. The CARD11-HOIP interaction is rendered TCR-inducible by the four autoinhibitory repressive elements in the CARD11 inhibitory domain and involves the CARD11 coiled-coil domain and two independent regions of HOIP. Interestingly, oncogenic CARD11 variants associated with diffuse large B cell lymphoma spontaneously induce Lin(Ub)-Bcl10 production to extents that correlate with their abilities to activate NF-κB and with their enhanced abilities to bind HOIP and Bcl10. Our results define molecular determinants that control the production of Lin(Ub)-Bcl10, an important signaling intermediate in TCR and oncogenic CARD11 signaling.

Citing Articles

NEMO Family of Proteins as Polyubiquitin Receptors: Illustrating Non-Degradative Polyubiquitination's Roles in Health and Disease.

Wu C Cells. 2025; 14(4).

PMID: 39996775 PMC: 11854354. DOI: 10.3390/cells14040304.


Met1-linked ubiquitination in cell signaling regulation.

Guo Y, Zhao Y, Cong Y Biophys Rep. 2024; 10(4):230-240.

PMID: 39281196 PMC: 11399889. DOI: 10.52601/bpr.2024.230030.


MALT1 substrate cleavage: what is it good for?.

Moud B, Ober F, ONeill T, Krappmann D Front Immunol. 2024; 15:1412347.

PMID: 38863711 PMC: 11165066. DOI: 10.3389/fimmu.2024.1412347.


Mechanisms underlying linear ubiquitination and implications in tumorigenesis and drug discovery.

Li J, Liu S, Li S Cell Commun Signal. 2023; 21(1):340.

PMID: 38017534 PMC: 10685518. DOI: 10.1186/s12964-023-01239-5.


TCR ligand potency differentially impacts PD-1 inhibitory effects on diverse signaling pathways.

Chan W, Cao Y, Zhao X, Schrom E, Jia D, Song J J Exp Med. 2023; 220(12).

PMID: 37796477 PMC: 10555889. DOI: 10.1084/jem.20231242.


References
1.
Pedersen S, Chan W, Jattani R, Mackie D, Pomerantz J . Negative Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181. Mol Cell Biol. 2015; 36(5):794-808. PMC: 4760215. DOI: 10.1128/MCB.00876-15. View

2.
Davis R, Brown K, Siebenlist U, Staudt L . Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001; 194(12):1861-74. PMC: 2193582. DOI: 10.1084/jem.194.12.1861. View

3.
Lim K, Yang Y, Staudt L . Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev. 2012; 246(1):359-78. PMC: 4094296. DOI: 10.1111/j.1600-065X.2012.01105.x. View

4.
Yang Y, Kelly P, Shaffer 3rd A, Schmitz R, Yoo H, Liu X . Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. Cancer Cell. 2016; 29(4):494-507. PMC: 6026033. DOI: 10.1016/j.ccell.2016.03.006. View

5.
Hayden M, Ghosh S . NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012; 26(3):203-34. PMC: 3278889. DOI: 10.1101/gad.183434.111. View